Based in Stockholm, Procella Therapeutics is an early stage biotechnology company focused on developing cardiac stem cell technology leveraging research from Harvard University and Karolinska Institutet with the aim of treating heart failure. Procella is collaborating with AstraZeneca to take our first cellular product candidate from pre-clinical stage to first-in-human studies and, if successful in early trials, further development towards commercial manufacture.